Company intelligence / Profile preview

eGlint

San Diego, California, United States

Ownership: Private
Development stage: Preclinical

Overview

eGlint has developed a rapid, multiplexed proteomics platform called ProteoNex that can quantify hundreds of biomarkers from small blood samples within minutes. Their first commercial focus appears to be real-time cytokine storm monitoring—a major unmet need in critical care medicine. No published clinical results or regulatory clearances are available as of early 2025.

Therapeutic areas: OtherImmunology
Modalities: Multiplexed biomarker detectionbiosensing platform for proteomics and cytokine monitoring
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on eGlint.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eGlint.

Explore the full profile